Attached files
| file | filename |
|---|---|
| 8-K - 8-K - BIO-TECHNE Corp | k8q.txt |
| EX-99.1 - PRESS RLEEASE DATED OCTOBER 25, 2011 - BIO-TECHNE Corp | release102411.txt |
SEGMENT INFORMATION
TECHNE CORPORATION AND SUBISIDARIES
(in thousands of $'s, except per share data)
Fiscal 2012
---------------- Increase
First Percent (Decrease) From
Quarter of Sales Fiscal 2011
------- -------- --------------
Sales 77,596 100% 9,651
Cost of sales 19,209 25% 3,859
------- ---- -----
Gross margin 58,387 75% 5,792
Gross margin percentage 75.2%
SG&A expense 10,773 14% 3,160
R&D expense 6,667 9% 48
Interest income (728) (1%) 119
Other non-operating ex., net 1,175 1% 918
------- ---- -----
17,887 23% 4,245
------- ---- -----
Earnings before income taxes 40,500 52% 1,547
Income taxes 12,979 17% 399
------- ---- -----
27,521 35% 1,148
======= ==== =====
Diluted earnings per share 0.74
Weighted average diluted shares
outstanding 37,170
BIOTECHNOLOGY (1)
(in thousands of $'s)
Fiscal 2012
---------------- Increase
First Percent (Decrease) From
Quarter of Sales Fiscal 2011
------- -------- --------------
Sales 72,303 100% 9,262
Cost of sales 16,465 23% 3,624
------- ---- -----
Gross margin 55,838 77% 5,638
Gross margin percentage 77.2%
SG&A expense 9,470 13% 2,984
R&D expense 6,469 9% 48
Interest income (609) (1%) 53
Exchange loss/gain 524 1% 1,029
------- ---- -----
15,854 22% 4,114
------- ---- -----
Pretax result 39,984 55% 1,524
======= ==== =====
(1) Includes R&D Systems' Biotechnology Division, R&D Systems Europe,
BiosPacific, R&D China, Boston Biochem and Tocris.
HEMATOLOGY
(in thousands of $'s)
Fiscal 2012
---------------- Increase
First Percent (Decrease) From
Quarter of Sales Fiscal 2011
------- -------- --------------
Sales 5,293 100% 389
Cost of sales 2,744 52% 235
------- ---- -----
Gross margin 2,549 48% 154
Gross margin percentage 48.2%
SG&A expense 480 9% 152
R&D expense 198 4% ----
Interest income (47) (1%) 6
------- ---- ----
631 12% 158
------- ---- ----
Pretax result 1,918 36% (4)
======= ==== ====
CORPORATE AND OTHER (2)
(in thousands of $'s)
Fiscal 2012 Increase
First (Decrease) From
Quarter Fiscal 2011
------- --------------
Interest income 72 (60)
Rental income 134 11
------- ----
206 (49)
SG&A expense 823 24
Other-Building expenses 587 31
Other-Equity Investment losses 198 (131)
------- ----
1,608 (76)
------- ----
Pretax result (1,402) 27
======= ====
(2) Unallocated corporate expenses and Techne's share of losses by Hemerus
Medical, LLC and Nephromics, LLC